Abbott to spin off its $8.5 billion nutrition business as a separate company
Abbott announced its intention to separate its nutrition business, with annual sales of about $8.5 billion, into an independent public company. Abbott shareholders will receive shares of the new company, and the deal is planned to close by the end of 2027.
Key points
- The new company will take the Similac, PediaSure, Pedialyte, Glucerna and Ensure brands, about 16,000 employees and 14 plants.
- The separation will take place through a distribution of the new company's shares to Abbott shareholders, a so-called spin-off, in which existing shareholders receive shares of the separated business.
- The same day, Abbott reported third-quarter sales growth of 14.5% on a reported basis and 7.0% on a comparable basis.
What is being separated
The new company will take the Similac, PediaSure, Pedialyte, Glucerna and Ensure brands, about 16,000 employees and 14 plants. It will be led by Daniel Salvadori, currently an executive vice president at Abbott.
After the split, Abbott itself will have sales of about $42 billion and about 106,000 employees.
Terms of the split
The separation will take place through a distribution of the new company's shares to Abbott shareholders, a so-called spin-off, in which existing shareholders receive shares of the separated business. The deal is intended to be tax-free for U.S. federal income tax purposes.
Abbott expects the combined dividends of the two companies to equal Abbott's dividend at the time of the split. Before the split, the company will incur one-time costs, the amount of which it will disclose later.
Alongside quarterly results
The same day, Abbott reported third-quarter sales growth of 14.5% on a reported basis and 7.0% on a comparable basis. Nutrition sales rose 5.1%.
The company narrowed its 2026 adjusted earnings per share forecast to a range of $5.50 to $5.55.
What to check next
The next step is the new company's registration statement with the SEC and approval by regulators and Abbott's board. These documents should show the new company's financials and dividend policy.
Original sources
Cite this article
The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.
Follow Abbott Laboratories
A notification in your browser or on your phone when we publish about Abbott Laboratories. Free, no email, no account, no app.
Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards
